11,095 Halozyme Therapeutics, Inc. $HALO Shares Purchased by Gibbs Wealth Management

Key Points

• Gibbs Wealth Management increased its Halozyme stake by 140% in the third quarter, purchasing 11,095 additional shares for a total holding of 19,020 shares valued at approximately $2.1 million. Institutional investors collectively own 97.79% of the company.
• Analyst sentiment is favorable, with Halozyme receiving a consensus “Moderate Buy” rating and an average price target of $99.55. Recent upgrades included HC Wainwright raising its target to $130 and Zacks moving the stock to “Strong Buy.”
• Halozyme reported strong quarterly results, posting $2.28 in EPS versus the $1.79 estimate and $481 million in revenue, up 47.7% year over year. The stock opened at $125.63, near its 52-week high of $126.23, while insiders sold $13.5 million in shares over the preceding 90 days.

Gibbs Wealth Management increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 140.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 19,020 shares of the biopharmaceutical company's stock after purchasing an additional 11,095 shares during the quarter. Gibbs Wealth Management's holdings in Halozyme Therapeutics were worth $2,100,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of America Corp DE acquired a new position in Halozyme Therapeutics during the second quarter valued at approximately $214,504,000. William Blair Investment Management LLC acquired a new position in Halozyme Therapeutics in the second quarter valued at about $196,540,000. Jupiter Topco LLC acquired a new position in shares of Halozyme Therapeutics during the second quarter worth approximately $105,570,000. Caisse de depot et placement du Quebec bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $83,940,000. Finally, Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 85.6% in the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company's stock valued at $251,890,000 after buying an additional 1,052,509 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Citigroup reissued a "market outperform" rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. HC Wainwright raised their price objective on Halozyme Therapeutics from $115.00 to $130.00 and gave the company a "buy" rating in a report on Wednesday, October 7th. Wells Fargo & Company upped their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a research report on Friday, August 7th. Weiss Ratings raised shares of Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, August 31st. Finally, Zacks Research raised Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $99.55.

Insider Buying and Selling

In related news, Director Matthew L. Posard sold 18,996 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the transaction, the director directly owned 58,839 shares of the company's stock, valued at $6,339,313.86. This trade represents a 24.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company's stock, valued at $82,482,605.40. This trade represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,852 shares of company stock valued at $13,538,046 over the last 90 days. Corporate insiders own 2.50% of the company's stock.

Halozyme Therapeutics Stock Up 0.9%

Shares of NASDAQ:HALO opened at $125.63 on Friday. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $126.23. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The stock has a 50 day moving average price of $111.37 and a 200-day moving average price of $87.03. The firm has a market capitalization of $14.26 billion, a P/E ratio of 37.50, a P/E/G ratio of 0.47 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same period in the previous year, the company posted $1.54 EPS. The firm's revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.31 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.